BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

OMER upcoming catalysts

Omeros Corporation: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 1 FDA event(s). Subscribe to OMER (.ics).

Drugs: OMS906

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Omeros Corporation OMERNCT06298955 Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuriaactive not recruiting25

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2025-12-23FDA approvalapprovedOMEROS CORP OMERYARTEMLEAApproved 2025-12-23: YARTEMLEA (BLA761152 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-04-14P2Omeros Corporation OMERNCT06209736 Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNC3 Glomerulopathy; Idiopathic Immune Complex-Mediated Glomerulonephritisterminated3
2025-12 est.P2Omeros Corporation OMERNCT05855083 Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMAThrombotic Microangiopathies; Hematopoietic Stem Cell Transplantationrecruiting18

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.